Industry: Life Sciences Region: Sweden Transaction Price: US $1million Transaction Method: Equity investment
Project Introduction:
The Group, with its headquarters in Sweden and wholly owned subsidiaries in the United States, operates under the philosophy of providing customers in the biopharmaceutical and research industries with specialized development tools that facilitate and save time in the development of new therapeutics and diagnostics.
The enzyme products produced by the company have been used by scientists around the world, and the innovative product forms have effectively promoted the development and quality control of biological drugs.
Experience Advantage:
The company has accumulated extensive expertise in the generation, purification and analysis of various fragments from different species and IgG subclasses in the development of antibode-specific enzymes. Based on this experience, the company provides a variety of services for antibody fragmentation programs.
Cooperation Intention:
The company hopes to collaborate with academic communities focused on characterizing new enzymes, developing new workflows and antibodies against novel targets.